Dr Michael Serzan (Dana-Farber Cancer Institute, Boston, USA), Dr Javier Puente (Hospital Clínico San Carlos, Madrid, Spain), Dr Guillermo de Velasco (University Hospital 12 de Octubre, Madrid, Spain), and Dr Alessandro Rametta (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) share insights on the latest advances in metastatic renal cell carcinoma (mRCC), including new data from ASCO 2025.
The panel highlights the sustained survival benefit of pembrolizumab in the adjuvant setting. They also reaffirm the importance of the CheckMate 214 trial, which continues to shape clinical practice through its comparison of nivolumab plus ipilimumab versus sunitinib in metastatic disease.
Dr Puente discusses the promise of emerging triplet regimens currently under investigation for metastatic clear cell RCC. The panel also explores the growing interest in HIF-2α inhibitors, which are showing encouraging efficacy. In contrast, while CAR T-cell therapy holds significant potential, its application in mRCC remains limited by ongoing challenges.
In closing, the experts underscore the rapid progress in biomarker research, emphasising the integration of multi-omics data and the transformative role of artificial intelligence in driving personalised treatment strategies and improving patient outcomes.
Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC) | |
Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial | |
Zanzalintinib + Nivolumab ± Relatlimab in Patients with Previously Untreated Clear Cell RCC: Results from an Expansion Cohort of the Phase 1b STELLAR-002 Study | |
Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study | |
Combination Casdatifan Plus Cabozantinib Expansion Cohort of Phase 1 ARC-20 Study in Previously Treated Patients with Clear Cell Renal Cell Carcinoma | |
ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results from the Phase 1 TRAVERSE Study | |
Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial | |
Biomarker related highlights for kidney cancer |